BSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹731.70
- Market cap
- ₹11,517 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.5×Sector 45.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Other management change announcements
All →Zydus Lifesciences Management Change
Zydus Lifesciences announced the resignation of Dr. Amrut Naik, President of International Markets, effective 7 November 2026. Mr. Christoph Stoller has been appointed to the same senior management role from 2 November 2026.
Vahh Chemicals Management Change
VAHH Chemicals Limited appointed Ms. Shubhangi Rajesh Gadia as Company Secretary and Compliance Officer, effective 01 November 2026. The appointment was approved at a board meeting held on 31 October 2026.
Capital India Finance Management Change
Capital India Finance reports that Senior Management Personnel Ravindran Menon resigned, ceasing to be associated with the company from close of business on 31 October 2026. The resignation letter is enclosed.
Bank of Maharashtra Management Change
Bank of Maharashtra disclosed that Chief General Manager Dinkar Sankpal ceased to hold the post at close of 31 October 2026 on superannuation. This is a senior management departure.
Seksaria Finance Management Change
Seksaria Finance's Company Secretary and Compliance Officer, Amar Hasmukh Trivedi, resigned effective close of business on 31 October 2026. The board accepted the resignation at its 29 October 2026 meeting.
Nova Iron & Steel Management Change
Nova Iron and Steel appointed Palak Jindal as independent director and re-appointed Hardev Chand Verma as non-executive director. Both changes are board-level management updates.